Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
40.71 USD | -0.61% | -3.11% | -14.98% |
May. 03 | Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $47 From $48, Keeps Neutral Rating | MT |
May. 02 | Transcript : Ultragenyx Pharmaceutical Inc., Q1 2024 Earnings Call, May 02, 2024 |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.98% | 3.4B | |
+4.03% | 111B | |
+11.43% | 105B | |
-12.65% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.29% | 16.96B | |
+2.47% | 13.7B | |
+36.22% | 12.45B |
- Stock Market
- Equities
- RARE Stock
- News Ultragenyx Pharmaceutical Inc.
- Transcript : Ultragenyx Pharmaceutical Inc. Presents at Barclays Gene Editing & Gene Therapy Summit 2023, May-24-2023 08